Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey

…, BR Blazar, R Arnold, N Kröger, J Passweg, J Halter… - Leukemia, 2015 - nature.com
Despite major improvements in allogeneic hematopoietic cell transplantation over the past
decades, corticosteroid-refractory (SR) acute (a) and chronic (c) graft-versus-host disease (…

[HTML][HTML] National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. The 2014 ancillary therapy and …

…, MED Flowers, JC Gea-Banacloche, JP Halter… - Biology of Blood and …, 2015 - Elsevier
The 2006 National Institutes of Health (NIH) Consensus paper presented recommendations
by the Ancillary Therapy and Supportive Care Working Group to support clinical research …

[HTML][HTML] Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease

…, S Gerull, A Buser, C Bucher, J Halter… - Biology of blood and …, 2010 - Elsevier
Cytomegalovirus (CMV) infection and graft-versus-host disease (GVHD) are important
complications after allogeneic hematopoietic stem cell transplantation (HSCT) with a clear link. …

Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature

…, AF Widmer, M Decker, I Steffen, J Halter… - Clinical infectious …, 2008 - academic.oup.com
Background .Respiratory syncytial virus (RSV) causes significant mortality in patients with
hematological diseases, but diagnosis and treatment are uncertain. Methods .We …

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells

…, C Jilg, K Wilhelm, C Leiber, S Gerull, J Halter… - Nature medicine, 2018 - nature.com
Individuals with acute myeloid leukemia (AML) harboring an internal tandem duplication (ITD)
in the gene encoding Fms-related tyrosine kinase 3 (FLT3) who relapse after allogeneic …

Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation

…, M Stern, M Paulussen, J Halter… - Blood, The Journal …, 2007 - ashpublications.org
We assessed incidence and risk factors of cardiovascular events in 265 patients undergoing
allogeneic hematopoietic stem-cell transplantation (HSCT) between 1980 and 2000 and …

First experience of SARS‐CoV‐2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study

…, D Golshayan, K Hadaya, J Halter… - American Journal of …, 2020 - Wiley Online Library
Immunocompromised patients may be at increased risk for complications of severe acute
respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. However, comprehensive data of …

Vaccination of allogeneic haematopoietic stem cell transplant recipients: report from the international consensus conference on clinical practice in chronic GVHD

…, H Einsele, J Gea-Banacloche, H Greinix, J Halter… - Vaccine, 2011 - Elsevier
Patients lose protective immunity to vaccine-preventable diseases after haematopoietic
stem cell transplantation (HSCT). Therefore, revaccination of HSCT recipients represents an …

[HTML][HTML] Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients

…, M Gonzalez-Vicent, I Espigado, J Halter… - …, 2011 - ncbi.nlm.nih.gov
During 2009, a new strain of A/H1N1 influenza appeared and became pandemic. A prospective
study was performed to collect data regarding risk factors and outcome of A/H1N1 in …

Vaccine-preventable infections among solid organ transplant recipients in Switzerland

…, N Goossens, F Haidar, J Halter… - JAMA Network …, 2023 - jamanetwork.com
Importance Vaccine responses are decreased in solid organ transplant (SOT) recipients,
and given the complexity of implementation, vaccination programs may be suboptimal. The …